Aberrant levels, post-translational modifications (PTMs), mislocalisation, and aggregation of tau and α-synuclein have been widely described in Alzheimer’s disease (AD) and related tauopathies and Parkinson’s disease (PD) and related synucleinopathies, respectively. This evidence concerns the gene MAPT and tauopathy.